European Commission announced on Friday it greenlighted biopharmaceutical company AbbVie Inc's purchase of pharmaceutical company Allergan Plc.
EU's competition commissioner Margrethe Vestager said the acquisition "will increase the choice of treatments and offer better prices for patients." The Commission approved the merger on condition that the Allergan is stripped of its product under development for treating inflammatory bowel diseases, in making sure the two companies merging doesn't affect the treatment of these illnesses.
The acquisition worth approximately $63 billion was announced by AbbieVie back in June.